TrialNature communications2026

Preclinical and clinical investigation of VES001, an oral small molecule sortilin receptor inhibitor for the treatment of frontotemporal dementia: a first-in-human randomized placebo-controlled phase 1 trial.

Louise Klem et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.